Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model

about

Synergistic Antimyeloma Activity of Dendritic Cells and Pomalidomide in a Murine Myeloma Model

Item

http://www.wikidata.org/entity/Q58801894

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@en

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@nl

type

Item

label

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@en

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@nl

prefLabel

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@en

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@nl

P1476

Synergistic Antimyeloma Activi ...... mide in a Murine Myeloma Model

@en

P2093

Hye-Seong Park

http://www.w3.org/2001/XMLSchema#string

Hyeoung-Joon Kim

http://www.w3.org/2001/XMLSchema#string

Hyun-Ju Lee

http://www.w3.org/2001/XMLSchema#string

Je-Jung Lee

http://www.w3.org/2001/XMLSchema#string

Manh-Cuong Vo

http://www.w3.org/2001/XMLSchema#string

Seoyun Yang

http://www.w3.org/2001/XMLSchema#string

Sung-Hoon Jung

http://www.w3.org/2001/XMLSchema#string

Tan-Huy Chu

http://www.w3.org/2001/XMLSchema#string

Thangaraj Jaya Lakshmi

http://www.w3.org/2001/XMLSchema#string

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic

Dendritic cells and the control of immunity

Dendritic cell-based vaccine efficacy: aiming for hot spots

T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation

United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy.

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.

Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

P304

1798

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2018.01798

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30123221

http://www.w3.org/2001/XMLSchema#string

P932

6085413

http://www.w3.org/2001/XMLSchema#string